SCHEMBL7595174

SCHEMBL7595174

CCC(O)N(O)C(CC)CO

nearest known ligand 0.30

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.30
TSHR P16473 1/20 0.30
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL321887 0.78 TSHR (0.41) TSHR
SCHEMBL29233004 0.70
SCHEMBL6547755 0.69 TSHR (0.33) TDP1TSHRLMNA
SCHEMBL9930528 0.68 TSHR (0.35) TSHR
SCHEMBL8069787 0.67
Water SCHEMBL1524782 0.67 LMNA (0.32) TDP1TSHRLMNA
SCHEMBL2490458 0.67
SCHEMBL9046 0.67
SCHEMBL8743481 0.66
SCHEMBL13452896 0.65 FDPS (0.35) TDP1TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1245249-A2 Use of a cationic amphipathic compound as a transfection agent, vaccine additive or drug Aventis Pasteur (FR) 2002-10-02 EP disclosed
EP-0769942-A1 USE OF A CATIONIC AMPHIPATHIC COMPOUND AS A TRANSFECTION AGENT, VACCINE ADDITIVE OR DRUG PASTEUR MERIEUX SERUMS ET VACCINS (FR) 1997-05-02 EP disclosed
WO-1996032102-A1 USE OF A CATIONIC AMPHIPATHIC COMPOUND AS A TRANSFECTION AGENT, VACCINE ADDITIVE OR DRUG PASTEUR MERIEUX SERUMS ET VACCINS (FR) 1996-10-17 WO disclosed